Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GLG Pharma develops proprietary technologies for oncology drug discovery. Their main focus is on creating advanced cancer cell culture systems that better replicate patient tumor profiles—enabling more predictive preclinical testing—and developing small molecule inhibitors targeting the STAT3 signaling pathway. Their lead compound(s) have shown good tolerability in preclinical toxicology studies. The company collaborates with academic centers such as Moffitt Cancer Center and has received funding from public sources to advance its pipeline toward clinical trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GLG Pharma.